Literature DB >> 25001105

Clostridium difficile recurrence is characterized by pro-inflammatory peripheral blood mononuclear cell (PBMC) phenotype.

Mary B Yacyshyn1, Tara N Reddy2, Lauren R Plageman1, Jiang Wu2, Amy R Hollar1, Bruce R Yacyshyn1.   

Abstract

Clostridium difficile infection (CDI) is a prevalent nosocomial and increasingly community-acquired problem. Little is known about the productive cellular response in patients. We used flow cytometry to define inflammatory (Th1 and Th17) and regulatory [Foxp3(+) T-regulatory (Treg)] cells present in circulating peripheral blood mononuclear cells (PBMC) from CDI patients. We consented 67 inpatients that tested either positive or negative for CDI and 16 healthy controls and compared their PBMC phenotypes. PBMC were collected, isolated, and stained for CD3, CD8 and either IL17 (Th17), IFN-γ (Th1) or Foxp3 (Treg) and analysed using flow cytometry. Twenty thousand events were collected in the lymphocyte gate (gate 1) and T-cell phenotypes were defined. CDI patients who clear the primary initial infection have greater numbers of non-CD3 PBMC. CDI patients who develop recurrence of CDI have a greater percentage of CD3(+)CD8(+), CD3(+)CD4(+)Foxp3 and fewer low granular CD3(-)Foxp3(+) PBMC. These patients have greater numbers of IFN-γ-producing lymphocytes, as well as PBMC phenotypes represented by increased IFN-γ- and IL17-co-expressing CD4(+)CD3(+). This initial pro-inflammatory phenotype decreases with repeated recurrence, demonstrating importance of timing of sample collection and history of symptoms. Patients with a history of recurrence had increased Foxp3(+)CD3(+)CD4(+) and IL17(+)CD3(+)CD4(+) populations. Hence, CDI recurrence is hallmarked by greater numbers of circulating CD3(+) lymphocytes skewed towards a Th1/Th17 inflammatory population as well as possible immune plasticity (Th17/Treg).
© 2014 The Authors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25001105      PMCID: PMC7304883          DOI: 10.1099/jmm.0.075382-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  41 in total

Review 1.  Clostridium difficile: biological therapies.

Authors:  Jessica Martin; Damian Mawer; Mark H Wilcox
Journal:  Curr Opin Infect Dis       Date:  2013-10       Impact factor: 4.915

Review 2.  Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options.

Authors:  Andrea Lo Vecchio; George M Zacur
Journal:  Curr Opin Gastroenterol       Date:  2012-01       Impact factor: 3.287

3.  Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.

Authors:  Hon Wai Koon; David Q Shih; Tressia C Hing; Jun Hwan Yoo; Samantha Ho; Xinhua Chen; Ciarán P Kelly; Stephan R Targan; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

4.  Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis.

Authors:  Yuko Ishida; Tsuneo Maegawa; Toshikazu Kondo; Akihiko Kimura; Yoichiro Iwakura; Shinichi Nakamura; Naofumi Mukaida
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

5.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Elena Deych; Carlos Gonzalez; Phillip I Tarr; David B Haslam
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

Review 6.  B-regulatory cells in autoimmunity and immune mediated inflammation.

Authors:  Zahava Vadasz; Tharwat Haj; Aharon Kessel; Elias Toubi
Journal:  FEBS Lett       Date:  2013-05-22       Impact factor: 4.124

7.  Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.

Authors:  Tanya M Monaghan; Adrian Robins; Alan Knox; Herbert F Sewell; Yashwant R Mahida
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

8.  Effects of Clostridium difficile toxin A and B on human T lymphocyte migration.

Authors:  Dan Wu; Antony George Joyee; Saravanan Nandagopal; Marianela Lopez; Xiuli Ma; Jody Berry; Francis Lin
Journal:  Toxins (Basel)       Date:  2013-05-03       Impact factor: 4.546

9.  Clostridium difficile modulates host innate immunity via toxin-independent and dependent mechanism(s).

Authors:  Nazila V Jafari; Sarah A Kuehne; Clare E Bryant; Mamoun Elawad; Brendan W Wren; Nigel P Minton; Elaine Allan; Mona Bajaj-Elliott
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

10.  Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis.

Authors:  Y R Mahida; A Galvin; S Makh; S Hyde; L Sanfilippo; S P Borriello; H F Sewell
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

View more
  9 in total

Review 1.  Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection.

Authors:  Alyse L Frisbee; William A Petri
Journal:  Trends Mol Med       Date:  2020-02-17       Impact factor: 11.951

Review 2.  Type 3 Immunity during Clostridioides difficile Infection: Too Much of a Good Thing?

Authors:  Mahmoud M Saleh; William A Petri
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

Review 3.  Pathogenic effects of glucosyltransferase from Clostridium difficile toxins.

Authors:  Yongrong Zhang; Hanping Feng
Journal:  Pathog Dis       Date:  2016-04-04       Impact factor: 3.166

4.  Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Associates With Functional Alterations in Circulating microRNAs.

Authors:  Tanya M Monaghan; Anna M Seekatz; Nicholas O Markham; Tung On Yau; Maria Hatziapostolou; Tahseen Jilani; Niki Christodoulou; Brandi Roach; Eleni Birli; Odette Pomenya; Thomas Louie; D Borden Lacy; Peter Kim; Christine Lee; Dina Kao; Christos Polytarchou
Journal:  Gastroenterology       Date:  2021-04-09       Impact factor: 33.883

Review 5.  Host Immune Responses to Clostridioides difficile: Toxins and Beyond.

Authors:  Britt Nibbering; Dale N Gerding; Ed J Kuijper; Romy D Zwittink; Wiep Klaas Smits
Journal:  Front Microbiol       Date:  2021-12-21       Impact factor: 5.640

6.  Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria.

Authors:  Peter J Eggenhuizen; Boaz H Ng; Janet Chang; Rachel M Y Cheong; Anusha Yellapragada; Wey Y Wong; Yi Tian Ting; Julie A Monk; Poh-Yi Gan; Stephen R Holdsworth; Joshua D Ooi
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

7.  Cysteine Protease-Mediated Autocleavage of Clostridium difficile Toxins Regulates Their Proinflammatory Activity.

Authors:  Yongrong Zhang; Shan Li; Zhiyong Yang; Lianfa Shi; Hua Yu; Rosangela Salerno-Goncalves; Ashley Saint Fleur; Hanping Feng
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-02-09

8.  Human Umbilical Mesenchymal Stem Cells Display Therapeutic Potential in Rheumatoid Arthritis by Regulating Interactions Between Immunity and Gut Microbiota via the Aryl Hydrocarbon Receptor.

Authors:  Xiaoya Li; Cheng Lu; Danping Fan; Xiangchen Lu; Ya Xia; Hongyan Zhao; Huihui Xu; Yongliang Zhu; Jingtao Li; Honglin Liu; Cheng Xiao
Journal:  Front Cell Dev Biol       Date:  2020-03-13

Review 9.  Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections.

Authors:  Isabelle Bekeredjian-Ding
Journal:  Front Immunol       Date:  2020-08-05       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.